Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum
Annals of Dermatology
; : S107-S111, 2023.
Article
在 En
| WPRIM
| ID: wpr-976673
Responsible library:
WPRO
ABSTRACT
Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with steroids, immunosuppressants, or a single biological agent such as infliximab, golimumab, or vedolizumab. For the first time in Korea, we report a successful treatment experience of pyoderma gangrenosum in UC using dual biological agents, vedolizumab and infliximab. We strategically targeted each of the intestinal and skin symptoms, with a specific biological agent based on the drug’s mechanism of action.